2 weeks Ago By ABMN Staff
Shares of United Therapeutics Co. ( NASDAQ:UTHR – Get Free Report ) reached a new 52-week high during trading on Wednesday after Oppenheimer raised their price target on the stock from $400.00 to $575.
00. Oppenheimer currently has an outperform rating on the stock. United Therapeutics traded as high as $363.
24 and last traded at $359.96, with a volume of 84265 shares. The stock had previously closed at $349.
23. UTHR has been the topic of a number of other research reports. The Goldman Sachs Group upped their target price on United Therapeutics from $218.
00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. HC Wainwright reiterated a “buy” rating and issued a $400.
00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $310.
00 to $321.00 in a research note on Thursday, July 11th. Finally, JPMorgan Chase & Co.
boosted their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st.
One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $350.
36. Read Our Latest Research Report on United Therapeutics Insider Buying and Selling at United Therapeutics Hedge Funds Weigh In On United Therapeutics Several hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC increased its position in shares of United Therapeutics by 13,769.
2% in the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after acquiring an additional 8,950 shares during the period. CWM LLC raised its stake in shares of United Therapeutics by 45.
7% in the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 210 shares during the last quarter. GAMMA Investing LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth about $43,000.
Van ECK Associates Corp lifted its holdings in shares of United Therapeutics by 3.9% during the fourth quarter. Van ECK Associates Corp now owns 10,064 shares of the biotechnology company’s stock worth $2,213,000 after purchasing an additional 379 shares during the period.
Finally, Victory Capital Management Inc. boosted its position in United Therapeutics by 309.7% in the fourth quarter.
Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock valued at $29,501,000 after buying an additional 101,419 shares during the last quarter. Institutional investors and hedge funds own 94.
08% of the company’s stock. United Therapeutics Trading Up 0.1 % The company has a debt-to-equity ratio of 0.
02, a quick ratio of 4.18 and a current ratio of 4.35.
The company’s fifty day moving average is $329.43 and its two-hundred day moving average is $277.00.
The company has a market cap of $15.98 billion, a price-to-earnings ratio of 17.03, a P/E/G ratio of 1.
25 and a beta of 0.55. United Therapeutics ( NASDAQ:UTHR – Get Free Report ) last issued its earnings results on Wednesday, July 31st.
The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.
48). The business had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.
87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.
87%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis.
During the same period last year, the business earned $5.24 EPS. On average, research analysts anticipate that United Therapeutics Co.
will post 24.86 EPS for the current year. About United Therapeutics ( Get Free Report ) United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. Read More Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
